Zebutinib Combined With Immunochemotherapy in the Treat of Newly Treated CLL Patients Without 17p-/TP53 Mutation

NCT04980859 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: Zebutinib&BR or Zebutinib&FCR

Sponsor

Nanfang Hospital, Southern Medical University